Simvastatin inhibits planktonic cells and biofilms of Candida and Cryptococcus species  by Brilhante, Raimunda Sâmia Nogueira et al.
OS
o
R
J
E
R
J
a
(
b
c
a
A
R
A
A
K
C
C
S
A
B
h
1b r a z j i n f e c t d i s . 2 0 1 5;1  9(5):459–465
w ww.elsev ier .com/ locate /b j id
The Brazilian Journal of
INFECTIOUS  DISEASES
riginal article
imvastatin  inhibits  planktonic  cells  and  bioﬁlms
f Candida  and  Cryptococcus  species
aimunda Sâmia Nogueira Brilhantea,b,∗, Erica Pacheco Caetanoa,
onathas  Sales de Oliveiraa, Débora de Souza Collares Maia Castelo-Brancoa,
lizabeth Ribeiro Yokobatake Souzaa, Lucas Pereira de Alencara,
ossana de Aguiar Cordeiroa,b, Tereza de Jesus Pinheiro Gomes Bandeiraa,
osé  Júlio Costa Sidrima,b, Marcos Fábio Gadelha Rochaa,c
Centro Especializado em Micologia Médica, Programa de Pós-Graduac¸ão em Microbiologia Médica, Universidade Federal do Ceará
UFC), Fortaleza, CE, Brazil
Programa de Pós-Graduac¸ão em Ciências Médicas, Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil
Programa de Pós-Graduac¸ão em Ciências Veterinárias, Universidade Estadual do Ceará (UECE), Fortaleza, CE, Brazil
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 2 April 2015
ccepted 1 June 2015
vailable online 26 June 2015
eywords:
andida
ryptococcus
imvastatin
ntifungal activity
ioﬁlm
a  b  s  t  r  a  c  t
The antifungal activity of some statins against different fungal species has been reported.
Thus, at the ﬁrst moment, the in vitro antifungal activity of simvastatin, atorvastatin
and  pravastatin was tested against Candida spp. and Cryptococcus spp. Then, in a second
approach, considering that the best results were obtained for simvastatin, this drug was eval-
uated in combination with antifungal drugs against planktonic growth and tested against
bioﬁlms of Candida spp. and Cryptococcus spp. Drug susceptibility testing was performed
using the microdilution broth method, as described by the Clinical and Laboratory Stan-
dards  Institute. The interaction between simvastatin and antifungals against planktonic
cells was analyzed by calculating the fractional inhibitory concentration index. Regarding
bioﬁlm susceptibility, simvastatin was tested against growing bioﬁlm and mature bioﬁlm of
one  strain of each tested yeast species. Simvastatin showed inhibitory effect against Candida
spp. and Cryptococcus spp. with minimum inhibitory concentration values ranging from 15.6
to  1000 mg L−1 and from 62.5 to 1000 mg L−1, respectively. The combination of simvastatin
with  itraconazole and ﬂuconazole showed synergism against Candida spp. and Cryptococ-
cus  spp., while the combination of simvastatin with amphotericin B was synergistic only
against Cryptococcus spp. Concerning the bioﬁlm assays, simvastatin was able to inhibit both
growing bioﬁlm and mature bioﬁlm of Candida spp. and Cryptococcus spp. The present studyshowed that simvastatin inhibits planktonic cells and bioﬁlms of Candida and Cryptococcusspecies.∗ Corresponding author at: Rua Barão de Canindé, 210, Montese, CEP: 60
E-mail address: brilhante@ufc.br (R.S.N. Brilhante).
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Introduction
The incidence of invasive fungal infections, especially those
caused by opportunistic fungi of the genus Candida and Cryp-
tococcus, has proportionally increased with the increase in
the number of hosts with impaired immunity.1–4 In addition,
in vitro resistance to antifungal drugs among Candida spp. and
Cryptococcus spp. strains recovered from humans and animals
has been reported.5–11
This scenario motivates the search for new compounds
with antifungal potential. Originally, the ﬁrst statins were
described as metabolites of microorganisms with the abil-
ity to lower blood cholesterol.12 Later, it was demonstrated
that these compounds reduce the growth of several fungal
species,13–15 including the yeasts Candida spp. and Cryptococcus
neoformans16 and the ﬁlamentous fungi Mucor spp. and Rhi-
zopus spp.17 In addition, it has also been reported that the
administration of statins to hospitalized patients increases
survival18 and decreases Candida burden in diabetic patients.19
Although the antifungal potential of statins has already
been addressed in previous reports, studies involving the
effect of statins on fungal bioﬁlms are needed to obtain a
better knowledge on the antifungal potential of these com-
pounds. Hence, this study evaluated the effect of the statins
simvastatin, atorvastatin, and pravastatin on planktonic cells
of Candida spp. and Cryptococcus spp. Considering that the best
results were obtained for simvastatin, this drug was evalu-
ated in combination with antifungal drugs against planktonic
growth. In addition, simvastatin was tested against bioﬁlms
of Candida spp. and Cryptococcus spp.
Materials  and  methods
Microorganisms
For this study, 51 strains of Candida spp. (16 Candida albicans;
12 Candida tropicalis; 11 Candida krusei;  12 Candida parapsilosis
sensu lato), and 25 strains of Cryptococcus spp. (13 C. neoformans
– serotypes A, D and AD; and 12 Cryptococcus gattii – serotypes
B and C) isolated from animals were used. The isolates belong
to the culture collection of the Specialized Medical Mycol-
ogy Center, Brazil. The purity and identity of the Candida spp.
strains were conﬁrmed by growth on chromogenic medium
and microscopical and biochemical features.20 For the Cryp-
tococcus spp. strains, capsule formation, melanin production,
and biochemical testing were evaluated and the serotype of
each strain was assessed by PCR.21
Susceptibility  testing  of  planktonic  cells
Susceptibility assays were performed using the broth microdi-
lution method, as described by the document M27-A3 of the
Clinical and Laboratory Standards Institute.22 The tests were
performed in duplicate and visually read after 48 h of incuba-
◦tion at 35 C. The strains C. parapsilosis ATCC 22019 and C. krusei
ATCC 6258 were included as quality control for all tests.22
Inocula were prepared to obtain a ﬁnal concentration
of 0.5–2.5 × 103 cells mL−1.22 The statins simvastatin (Medley 1 5;1  9(5):459–465
Indústria Farmacêutica Ltda, Campinas, SP, Brazil), atorvas-
tatin (Laboratórios Pﬁzer Ltda, São Paulo, SP, Brazil), and
pravastatin (Bristol-Myers-Squibb, Nova York, NY, USA) and
the antifungal drugs amphotericin B (Sigma Chemical Corpo-
ration, St Louis, USA), itraconazole (Janssen Pharmaceutica,
Beerse, Belgium), and ﬂuconazole (Pﬁzer Pharmaceuticals,
New York, USA) were tested against all strains.
To obtain the stock-solutions of each drug, atorvas-
tatin, pravastatin, and ﬂuconazole were diluted with ster-
ile distilled water, and amphotericin B and itracona-
zole were diluted with dimethylsulfoxide (DMSO). Sim-
vastatin was activated from its lactone prodrug form
through hydrolysis in ethanolic NaOH (15% (v/v) ethanol,
0.25% (w/v) NaOH), at 60 ◦C, for 1 h.15 The concentra-
tion range tested was 3.9–2000 g mL−1 for simvastatin,
19.5–10,000 g mL−1 for atorvastatin, 97.6–50,000 g mL−1 for
pravastatin, 0.0312–64 g mL−1 for amphotericin B and itra-
conazole, and 0.25–256 g mL−1 for ﬂuconazole. The minimum
inhibitory concentration (MIC) was deﬁned as the lowest drug
concentration able to inhibit 100% of fungal growth for ampho-
tericin B and 50% inhibition of fungal growth when compared
to the free-drug azoles22 and statins control.
As simvastatin provided the best antifungal results, we
evaluated the interaction between this drug and the antifungal
drugs against the tested yeasts. For drug interaction studies,
simvastatin was tested with each azole by broth microdilution
method, using the MIC of each tested drug alone as the highest
concentrations tested in combination. The concentrations of
the drugs in combination ranged from 0.03 to 1000, 0.00024 to
2, 0.00006 to 64 and 0.00048 to 256 g mL−1 for simvastatin,
amphotericin B, itraconazole and ﬂuconazole, respectively.
The reading criteria were the same as for the antifungal drugs
alone, namely 100% inhibition when combined with ampho-
tericin B and 50% inhibition when combined with azoles. The
interaction between the drugs was analyzed by calculating the
fractional inhibitory concentration index (FICI), with values
≤0.5 indicating synergism.23
Susceptibility  test  of  sessile  cells
Simvastatin was tested against growing bioﬁlms and mature
bioﬁlms of Candida spp. and Cryptococcus spp. Amphotericin
B and itraconazole were used in all tests as control drugs
for bioﬁlm inhibition. The tests were performed in tripli-
cate using one bioﬁlm-producing strain of each tested fungal
species (C. albicans, C. tropicalis, C. parapsilosis, C. krusei, C. neo-
formans and C. gattii), according to the methodology described
by Chatzimoschou et al.,24 with some modiﬁcations. Brieﬂy,
strains were grown on Sabouraud dextrose agar for 48 h at
30 ◦C and then subcultured into Sabouraud dextrose broth for
24 h, at 30 ◦C, under agitation at 150 rpm. After this period,
the suspensions were centrifuged at 3000 rpm for 10 min,
the supernatant was discarded, and the pellet was washed
twice with sterile PBS. Then, the pellet was resuspended in
RPMI 1640 medium (Gibco-BRL, USA), reaching a concentra-
tion of 1 × 106 cells mL−1. Tests were performed in 96-well
polystyrene plates.
To evaluate the effect of simvastatin, amphotericin B, and
itraconazole on growing bioﬁlm, 100 L of the fungal suspen-
sion was exposed to 100 L of simvastatin and incubated at
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Table 1 – Geometric means of the minimum inhibitory concentrations (MIC) of statins and antifungal agents against
Candida spp. and Cryptococcus spp.
Strains (n) MIC geometric mean (g mL−1)
Statins Antifungals
Simvastatin Atorvastatin Pravastatin Amphotericin B Itraconazole Fluconazole
Candida species
C. albicans (16) 29.45 52.06 2159.24 0.561 5.992 21.357
C. tropicalis (12) 70.12 165.34 21022.41 0.343 15.021 82.346
C. krusei (11) 567.16 755.06 >50,000 1.624 0.072 12.126
C. parapsilosis sensu lato (12) 235.97 1491.37 >50,000 0.707 0.059 0.891
Cryptococcus species
C. neoformans Aa (11) 500 3886.02 44079.56 0.536 0.189 6.498
C. neoformans D (1) 250 >10,000 >50,000 0.25 0.25 8
C. neoformans AD (1) 62.5 >10,000 >50,000 0.125 0.5 8
C. gatti B (11) 500 5325.21 44079.56 0.735 0.315 34.562
C. gatti C (1) 500 >10,000 >50,000 1 1 64
a Serotypes.
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w5 ◦C for 48 h. The tested concentrations were based on the
IC  obtained for each drug against fungal planktonic growth,
ncluding MIC, 10xMIC and 50xMIC. On the other hand, to
valuate the effect of simvastatin and the antifungals alone
gainst mature bioﬁlm, 100 L of the fungal suspension was
dded to 100 L of RPMI 1640 medium and incubated at 35 ◦C
or 48 h. Then, the mature bioﬁlms were exposed to simvas-
atin, amphotericin B, and itraconazole and incubated at 35 ◦C
or 48 h. The tested concentrations against mature bioﬁlms
ere 10xMIC, 50xMIC and 100xMIC. For all tests, drug-free
rowth control for each strain was included.
After 48 h of drug exposure, the growing and mature
ioﬁlms were submitted to the following procedures: super-
atants were collected and reserved for further analysis, and
lates were washed twice with sterile PBS Tween 20 (0.05%,
/v) solution to remove non-adhered cells. Then, the bioﬁlm
iability was evaluated through XTT assay, according to Mar-
inez and Casadevall,25 with modiﬁcations. Stock solutions
f XTT (1 mg  mL−1) were previously prepared, ﬁltrated and
tocked at −20 ◦C, until used. Menadione (Sigma) (0.4 mM in
cetone) was prepared at the moment of use. Afterwards, 50 L
f sterile PBS, 75 L of XTT solution, and 6 L of menadione
olution were added to each well. Plates were incubated at
5 ◦C during 5 h, in the dark, and then XTT was all transferred
o a new plate and read in a spectrophotometer at 492 nm.
tatistical  analysis
or analysis of the MIC  data of drugs against planktonic cells,
tudent’s t test for independent and paired samples was used.
o check the variation of the MIC  values of the drugs in com-
ination, as well as the FICI value, Student’s t test for paired
amples was also used. Regarding the bioﬁlm assay, all tests
ere made in triplicate and results were evaluated by ANOVA
nd Tukey’s multiple comparison post-test. p-Values < 0.05
ere considered statistically signiﬁcant.Results
Susceptibility  test  of  planktonic  cells
Among the tested statins, simvastatin showed the lowest
MIC, with geometric means varying from 29.45 to 567.16 and
from 62.5 to 500 mg  L−1 against the genera Candida and Cryp-
tococcus, respectively (Table 1). Atorvastatin showed better
results against Candida species, when compared to Crypto-
coccus spp., with MIC geometric means varying from 52.06
to 1682.37 mg  L−1 against Candida spp. and from 3886.02 to
>10,000 g mL−1 against Cryptococcus spp. (Table 1). As for
pravastatin, the MIC  geometric means varied from 2159.24
to >50,000 mg  L−1 against Candida spp. and from 44079.56 to
>50,000 mg L−1 against Cryptococcus (Table 1). MIC geometric
means for the classic antifungals against Candida spp. varied
from 0.343 to 1.624 mg  L−1 for amphotericin B, from 0.046 to
15.021 mg  L−1 for itraconazole, and from 0.659 to 82.346 mg  L−1
for ﬂuconazole. MIC  geometric means for classic antifungals
against Cryptococcus spp. varied from 0.125 to 0.735 mg  L−1 for
amphotericin B, from 0.189 to 1 mg  L−1 for itraconazole, and
from 6.498 to 64 mg  L−1 for ﬂuconazole (Table 1).
Results for the in vitro interaction between simvastatin
and antifungal drugs against these yeasts are shown in
Table 2. In general, a synergistic interaction was observed
between simvastatin and both azoles against C. albicans
(n = 10/10), C. tropicalis (n = 11/11) and C. parapsilosis sensu lato
(n = 12/12) (p < 0.05). Concerning C. krusei,  only the combina-
tion of simvastatin and itraconazole was synergistic (n = 9/10)
(p < 0.05). As for Cryptococcus spp., synergistic interactions
were observed between simvastatin and the three antifungals
tested against C. gattii (simvastatin/amphotericin B and sim-
vastatin/ﬂuconazole: n = 7/7; simvastatin/itraconazole: n = 5/7)
and C. neoformans (simvastatin/amphotericin B: n = 11/11;
simvastatin/itraconazole: n = 9/11; simvastatin/ﬂuconazole:
n = 10/11) (p < 0.05).
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Table 2 – Geometric means of the minimum inhibitory concentrations (MIC) of the combination of simvastatin and the
antifungal amphotericin B, itraconazole, or ﬂuconazole against Candida spp. and Cryptococcus spp.
Species (n) Drugs MIC (isolated) (g mL−1) MIC (combination) (g mL−1) FICI Number of strains
showing synergism
SIM Antifungal SIM Antifungal
Candida albicans (10)
SIM/AMB 29.11 0.616 24.06 0.595 1.741 0/10
SIM/ITC 29.11 9.189 1.042 0.329 0.071 10/10
SIM/FLC 29.11 21.112 1.695 0.116 0.116 10/10
Candida tropicalis (11)
SIM/AMB 75.47 0.3426 55.637 0.354 1.37 1/11
SIM/ITC 75.47 15.021 1.327 0.266 0.035 11/11
SIM/FLC 75.47 82.347 4.425 4.832 0.117 11/11
Candida krusei (10)
SIM/AMB 574.35 1.624 435.28 1.231 1.515 0/10
SIM/ITC 574.35 0.072 116.61 0.014 0.416 9/10
SIM/FLC 574.35 12.126 233.26 4.925 0.812 3/10
Candida parapsilosis sensu lato (12)
SIM/AMB 235.97 0.707 78.74 0.236 0.667 7/12
SIM/ITC 235.97 0.059 41.68 0.010 0.353 12/12
SIM/FLC 235.97 0.891 49.58 0.187 0.420 12/12
Cryptococcus neoformans (11)
Serotypes: A(9); D(1); AD(1) SIM/AMB 388.6 0.4139 35.42 0.0377 0.182 11/11
SIM/ITC 388.6 0.1943 70.86 0.0354 0.365 9/11
SIM/FLC 388.6 6.622 21.38 0.3648 0.11 10/11
Cryptococcus gattii (7)
Serotypes: B(6); C(1) SIM/AMB 500 0.8203 19.025 0.0312 0.076 7/7
SIM/ITC 500 0.4102 84.0803 0.0689 0.336 5/7
SIM/FLC 500 39.008 38.051 2.972 0.152 7/7
azoleSIM, simvastatin; AMB, amphotericin B; ITC, itraconazole; FLC, ﬂucon
concentration index.
Susceptibility  test  of  sessile  cells
Regarding the action of simvastatin against bioﬁlm of Candida
spp., simvastatin inhibited growing bioﬁlms at concentrations
greater than 10xMIC (Fig. 1). Amphotericin B caused signif-
icant decrease in metabolic activity of growing bioﬁlms at
10xMIC and 50xMIC, while itraconazole caused inhibition at
all tested concentrations (p < 0.05). As for mature bioﬁlms,
simvastatin caused signiﬁcant decrease in metabolic activity
(Fig. 1) (p < 0.05), at concentrations above 50xMIC. Ampho-
tericin B inhibited mature bioﬁlms at all tested concentrations,
while itraconazole only at 50xMIC and 100xMIC (p < 0.05).
Regarding the genus Cryptococcus, simvastatin inhibited
growing bioﬁlms at all tested concentrations (Fig. 2) (p < 0.05),
similar to what was observed when amphotericin B and itra-
conazole were used (p < 0.05). Concerning mature bioﬁlms,
simvastatin caused signiﬁcant decrease in metabolic activity
of Cryptococcus bioﬁlm at 50xMIC and 100xMIC (Fig. 2) (p < 0.05).
Amphotericin B inhibited mature bioﬁlms at all tested concen-
trations (p < 0.05), while itraconazole did not decrease bioﬁlm
metabolic activity at any tested concentration.Discussion
This study shows the inhibitory activity of simvastatin on
the growth of yeasts of the genera Candida and Cryptococcus; MIC, minimum inhibitory concentration; FICI, fractional inhibitory
with an inhibitory effect against both planktonic cells and
bioﬁlms. The MICs of simvastatin against C. albicans and C.
tropicalis were similar to the serum levels of the drug, when
administered to control blood cholesterol.26 C. albicans and C.
tropicalis are important fungal pathogens commonly isolated
from candidemia.27,28 Simvastatin and atorvastatin have been
described inhibiting Candida spp. and the ﬁlamentous fun-
gus Aspergillus fumigatus.13 This work conﬁrms the action of
these two drugs, especially simvastatin against Candida spp.
and Cryptococcus spp. However, the growth of these fungi was
not inhibited by pravastatin. The use of statins deregulates cel-
lular production of isoprenoid,13 which leads to mitochondrial
dysfunction, respiratory deﬁcit,29 and changes in lipid struc-
ture and in the dynamics of plasma membrane of C. albicans
cells.30
There is no synergistic interaction when simvastatin is
associated with amphotericin B against most Candida spp.
strains. Statins reduce the amount of fungal ergosterol, which
may lead to decreased activity of amphotericin B, since ergo-
sterol is the target molecule for this antifungal drug and a
decrease in the amount of this molecule is one of the mech-
anisms developed by amphotericin B resistant Candida spp.
However, synergism between simvastatin and amphotericin B
was observed against strains of Cryptococcus spp., in line with
previous reports with the ﬁlamentous fungi Rhizopus oryzae
and Aspergillus ﬂavus.31 These contradictory ﬁndings still need
to be elucidated.
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Fig. 1 – In vitro effect of simvastatin (SIM), amphotericin B
(AMB), and itraconazole (ITC) at 3 different concentrations
on bioﬁlm formation (A) and mature bioﬁlm (B) of Candida
spp. Black bars: positive control; MIC: minimum inhibitory
concentration. Absorbance of XTT (492 nm). *Represents
statistically signiﬁcant difference (p < 0.05) when compared
to the positive control. Data expressed as mean ± SEM.
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Fig. 2 – In vitro effect of simvastatin (SIM), amphotericin B
(AMB), and itraconazole (ITC) at 3 different concentrations
on bioﬁlm formation (A) and mature bioﬁlm (B) of
Cryptococcus spp. strains. Black bars: positive control; MIC,
minimum inhibitory concentration. Absorbance of XTT
(492 nm). *Represents statistical signiﬁcant difference
(p < 0.05) when compared to the positive control. Data
expressed as mean ± SEM.In general, when simvastatin is associated with azoles (i.e.
traconazole or ﬂuconazole) there is synergism against strains
f Candida spp. and Cryptococcus spp. However, probably due
o the intrinsic resistance of C. krusei to ﬂuconazole, syner-
ism between simvastatin and ﬂuconazole was not observed
gainst this Candida species. The interaction between statins
nd azoles has been reported against the yeasts Saccharomyces
erevisiae32 and Candida spp.,33 and the ﬁlamentous fungi
spergillus spp., Mucor spp. and Rhizopus spp.17,33 Synergism
etween these two pharmacological groups is most likely
ssociated with the combined action of the drugs in reduc-
ng fungal ergosterol, by acting at different moments in the
athway of ergosterol biosynthesis.11 In addition, the reduc-
ion of endogenous sterol due to the action of statins increases
ell membrane permeability in order to increase absorption of
xogenous sterol, as a compensatory mechanism, and, simul-
aneously, the entrance of azoles in the cell is facilitated.34
Bioﬁlm production is considered an important virulence
actor of Candida spp.35 and it contributes for the persistence
f infections.36 It has been demonstrated that simvastatin also
nhibits growing and mature bioﬁlms of Candida spp. and Cryp-
ococcus spp. strains when used alone. Liu et al.37 showed that
imvastatin inhibited bioﬁlm production of C. albicans after
6-h-incubation, suggesting that at least one mechanism of
nhibition involves interference with ergosterol biosynthesis.
n the other hand, there are no reports of the effect of sim-
astatin on bioﬁlms of Cryptococcus spp. Additional studies are
eeded to better understand the action of simvastatin against
east bioﬁlms.Studies have shown that amphotericin B inhibits fun-
gal bioﬁlms25,38 causing apoptosis of the cells in Candida
bioﬁlms.39 In our study, growing and mature bioﬁlms of Can-
dida spp. and Cryptococcus spp. were inhibited by amphotericin
B. Although many  authors have reported that azoles do not
inhibit fungal bioﬁlms,25,38 the present study demonstrated
the inhibition of growing and mature bioﬁlms of Candida spp.
by itraconazole. As for Cryptococcus spp., itraconazole only
inhibited growing bioﬁlms.
Although several reports have demonstrated in vitro activ-
ity of statins agents against many  clinical relevant yeast
and mold species, as well as the synergistic effect of statins
with different antifungal drugs, clinical studies are scarce.40
Spanakis et al.19 showed that use of statins decreased the inci-
dence of cultures positive for Candida species among patients
with type 2 diabetes mellitus who underwent gastrointesti-
nal surgery. In contrast, no beneﬁcial effects were observed
for statins in a study of patients with candidemia.41 How-
ever, these studies were performed with different patient
groups and were inconclusive. Thus, further studies aiming
to evaluate the beneﬁts of statin in antifungal therapy are
required.
The present study showed the activity of statins against
Candida and Cryptococcus species, with particular emphasis on
simvastatin, isolated and combined with classical antifungals.
In addition, it was also demonstrated that simvastatin was
able  to inhibit growing and mature bioﬁlms of Candida spp.
and Cryptococcus spp.
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